Skip to content
Institutional Investor early-stage Series A-D growth late-stage Est. 2004

New Science Ventures

Venture capital firm investing in breakthrough science companies in life sciences and IT

πŸ“ New York City, United States

About This Fund

Venture capital firm investing in breakthrough science companies in life sciences and IT. The firm focuses on early and late-stage companies with novel scientific approaches addressing unmet needs. It invests in life sciences and information technology sectors, seeking companies with differentiated value propositions and strong management teams. The firm focuses on fundamental, science-based innovation with strong IP protection, often taking contrarian views and venturing outside traditional tech hubs. They build teams that fit the companies’ stage of development, employing virtual business models. The firm looks for the right investment teams and syndicates, willing to lead, follow, or be sole investors, and are patient, continuing to support their companies through value inflection points.

Investment Focus

Sectors
life sciences (therapeutics medical devices in cardiovascular oncology respiratory diseases infectious diseases dermatology autoimmune; pharmaceuticals biologics diagnostics) information technology (high-performance semiconductors cellular infrastructure storage infrastructure data analytics/AI IoT sensor networks enterprise software)
Stages
early-stage Series A-D growth late-stage
Check Size $10M-$50M
Geography
USA Europe

What They Look For

science-based innovations with strong IP protection addressing significant unmet market needs; companies outside traditional tech/life sciences hubs; virtual business models; US and Europe focus

Preparing to pitch New Science Ventures?

CrackTheDeck analyzes your pitch deck before the meeting β€” structure, narrative, investor fit.

Analyze My Deck β†’